A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorJun Zhang, MD, PhD
About this trial
NSCLC patients with low expression level of PD-L1, esp. those with its level less than 1%, do not derive much benefit from anti-PD-1/L1 therapy (e.g. atezoilzumab). In this study, investigators hypothesize that the combination of cabozantinib (a multi-kinase inhibitor) and atezolizumab will result in better therapeutic value.
Eligibility criteria
Qualifiers
Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent
Males and females age ≥ 18 years
ECOG Performance Status 0 - 1
Pathologically confirmed advanced/metastatic NSCLC, with PD-L1<1% based on IHC using 22C3 antibody
Disqualifiers
Simultaneously enrolled in any therapeutic clinical trial
Current or anticipating use of other investigational agents while participating in this study
Treatment with investigational therapy within 28 days prior to initiation of study treatment
Diagnosed with a psychiatric illness or is in a social situation that would limit compliance with study requirements
Trial design
Treatments tested in this trial
- Cabozantinib
- Atezolizumab
Treatment groups
40 Participants
are divided into 1 treatment groupSponsors and collaborators
Jun Zhang, MD, PhD
Lead sponsor
University of Kansas Medical Center
Sponsor institution
Exelixis
Collaborator
Genentech, Inc.
Collaborator
Source ClinicalTrials.gov